Get the Stockscreener App
1.85
0.54%
-0.01
After Hours:
1.89
0.04
+2.16%
Gri Bio Inc stock is traded at $1.85, with a volume of 117.13K.
It is down -0.54% in the last 24 hours and up +2.21% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.86
Open:
$1.86
24h Volume:
117.13K
Relative Volume:
0.10
Market Cap:
$4.65M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0345
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-7.50%
1M Performance:
+2.21%
6M Performance:
+39.10%
1Y Performance:
-73.03%
1-Day Range:
$1.80
$1.90
1-Week Range:
$1.80
$2.05
52-Week Range:
$1.10
$30.43
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.85 | 4.68M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Why GRI Bio Inc. stock is considered a top pickAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
Applying big data sentiment scoring on GRI Bio Inc.July 2025 Review & Consistent Profit Trade Alerts - newser.com
Momentum divergence signals in GRI Bio Inc. chartWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Can volume confirm reversal in GRI Bio Inc.Trade Risk Assessment & AI Based Trade Execution Alerts - newser.com
Should you wait for a breakout in GRI Bio Inc.2025 Volatility Report & Short-Term Trading Alerts - newser.com
Is GRI Bio Inc. stock attractive for growth ETFs2025 Performance Recap & Entry Point Strategy Guides - newser.com
Hind oil exploration is this a multibagger betTechnical Breakout Signals & Budget Friendly Trading Alerts - earlytimes.in
Will GRI Bio Inc. stock recover after recent dropTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Live market analysis of GRI Bio Inc.Dip Buying & Short-Term Trading Alerts - newser.com
Is Now a Good Time to Buy Shree Hari Chemicals Export Limited Stock Key Indicators ReviewedBollinger Bands Signals & Big Gains Small Capital - earlytimes.in
Is GRI Bio Inc. stock safe for conservative investorsMarket Risk Summary & Community Verified Watchlist Alerts - The British Mountaineering Council
GRI Bio (NASDAQ:GRI) Price Target Raised to $35.00 at Ascendiant Capital Markets - Defense World
GRI Bio's Price Target Raised by Ascendiant Capital | GRI Stock News - GuruFocus
S P Trends: How do insiders feel about Nova Minerals Limited Depositary ReceiptJuly 2025 Review & Expert Verified Stock Movement Alerts - خودرو بانک
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):